NASDAQ:ALDX Aldeyra Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.12 -0.29 (-3.91 %) (As of 10/1/2020 04:30 PM ET) Add Compare Share Today's Range$7.09Now: $7.12▼$7.5150-Day Range$5.85MA: $6.80▼$7.5352-Week Range$1.48Now: $7.12▼$8.05Volume607,621 shsAverage Volume735,705 shsMarket Capitalization$275.07 millionP/E RatioN/ADividend YieldN/ABeta2.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAldeyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.67, Aldeyra Therapeutics has a forecasted upside of 267.3% from its current price of $7.26.Amount of Analyst CoverageAldeyra Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesAldeyra Therapeutics has received 452 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAldeyra Therapeutics has received 365 “underperform” votes. (Add your “underperform” vote.)Community SentimentAldeyra Therapeutics has received 55.32% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote “Outperform” if you believe ALDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAldeyra Therapeutics does not currently pay a dividend.Dividend GrowthAldeyra Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aldeyra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $13,600,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 15.00% of the stock of Aldeyra Therapeutics is held by insiders.Percentage Held by Institutions37.91% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aldeyra Therapeutics are expected to grow in the coming year, from ($1.27) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aldeyra Therapeutics is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aldeyra Therapeutics is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAldeyra Therapeutics has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.17 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALDX Previous Symbol CUSIPN/A CIK1341235 Webwww.ampliphibio.com Phone781-761-4904Debt Debt-to-Equity Ratio0.26 Current Ratio14.52 Quick Ratio14.52Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book4.14Profitability EPS (Most Recent Fiscal Year)($2.05) Net Income$-60,830,000.00 Net MarginsN/A Return on Equity-100.83% Return on Assets-68.42%Miscellaneous Employees15 Outstanding Shares38,633,000Market Cap$275.07 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $7.12 -0.29 (-3.91 %) (As of 10/1/2020 04:30 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ALDX News and Ratings via Email Sign-up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions How has Aldeyra Therapeutics' stock price been impacted by Coronavirus? Aldeyra Therapeutics' stock was trading at $2.79 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALDX shares have increased by 155.2% and is now trading at $7.12. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Aldeyra Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aldeyra Therapeutics. When is Aldeyra Therapeutics' next earnings date? Aldeyra Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Aldeyra Therapeutics. How were Aldeyra Therapeutics' earnings last quarter? Aldeyra Therapeutics, Inc (NASDAQ:ALDX) announced its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.09. View Aldeyra Therapeutics' earnings history. What price target have analysts set for ALDX? 6 analysts have issued 1 year price objectives for Aldeyra Therapeutics' stock. Their forecasts range from $15.00 to $33.00. On average, they expect Aldeyra Therapeutics' share price to reach $26.67 in the next year. This suggests a possible upside of 274.5% from the stock's current price. View analysts' price targets for Aldeyra Therapeutics. Are investors shorting Aldeyra Therapeutics? Aldeyra Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 817,300 shares, an increase of 30.8% from the August 15th total of 624,700 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is currently 0.7 days. View Aldeyra Therapeutics' Short Interest. Who are some of Aldeyra Therapeutics' key competitors? Some companies that are related to Aldeyra Therapeutics include Supernus Pharmaceuticals (SUPN), NGM Biopharmaceuticals (NGM), Karyopharm Therapeutics (KPTI), Akero Therapeutics (AKRO), Phathom Pharmaceuticals (PHAT), Innoviva (INVA), Arcturus Therapeutics (ARCT), Nabriva Therapeutics (NBRV), Kiniksa Pharmaceuticals (KNSA), Esperion Therapeutics (ESPR), BioXcel Therapeutics (BTAI), Zogenix (ZGNX), Athenex (ATNX), Nkarta (NKTX) and Constellation Pharmaceuticals (CNST). View all competitors. What other stocks do shareholders of Aldeyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), BioNano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), AEterna Zentaris (AEZS), Novan (NOVN) and OrganiGram (OGI). Who are Aldeyra Therapeutics' key executives? Aldeyra Therapeutics' management team includes the following people: Todd C. Brady, M.D., Ph.D., Chief Executive Officer and Director (Age 48)Joshua Reed, Chief Financial Officer (Age 47)David McMullin, Chief Commercial Officer (Age 45)James A. Gow, M.D., Senior Vice President of Clinical Development (Age 53)Stephen G. Machatha, Ph.D., Senior Vice President, Technical Operation (Age 43) What is Aldeyra Therapeutics' stock symbol? Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX." How do I buy shares of Aldeyra Therapeutics? Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aldeyra Therapeutics' stock price today? One share of ALDX stock can currently be purchased for approximately $7.12. How big of a company is Aldeyra Therapeutics? Aldeyra Therapeutics has a market capitalization of $275.07 million. The biotechnology company earns $-60,830,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis. Aldeyra Therapeutics employs 15 workers across the globe. What is Aldeyra Therapeutics' official website? The official website for Aldeyra Therapeutics is www.ampliphibio.com. How can I contact Aldeyra Therapeutics? Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected] This page was last updated on 10/1/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
